A new study published in JAMA Network Open explores how cannabis legalization, both medical and recreational, is affecting the prescription of mental health medications in the U.S. The findings reveal a complex relationship, with cannabis laws leading to both decreased benzodiazepine prescriptions and increased use of antidepressants and antipsychotics. This underscores the need for further research into the broader impact of cannabis legalization on mental health treatment.
Neurocrine Biosciences’ experimental drug, NBI-1117568, demonstrated positive results in a Phase 2 clinical trial for schizophrenia, showing a significant reduction in symptoms compared to placebo. The drug’s potential as a safer alternative to atypical antipsychotics has sparked optimism among analysts, leading to an upgrade in the company’s stock.
Antipsychotic use in people with dementia is associated with increased risks of various serious health outcomes, including stroke, blood clots, heart attack, pneumonia, and acute kidney injury. These risks are particularly high in the early stages of treatment. Antipsychotics are commonly prescribed for behavioral and psychological symptoms of dementia, but their use should be carefully considered due to the potential for adverse effects. Further research is needed to explore safer alternatives for managing these symptoms.
